Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, is dedicated to developing and manufacturing a diverse range of pharmaceutical products primarily for the US, Canada, and other regulated and emerging markets. With a robust portfolio of 61 ANDA and 22 CMO/CDMO commercial products approved for distribution in the USA, Senores focuses on complex generics certified by global regulatory authorities.
Operating in over 40 countries, the company holds approvals from regulatory bodies in more than 10 countries for its manufacturing facility in Chhatral, catering to emerging markets with a wide array of product registrations and applications. Senores specializes in critical care injectables, Active Pharmaceutical Ingredients (API), and generic drugs for emerging markets, showcasing its commitment to global healthcare. The company’s manufacturing facilities in both the US and India adhere to stringent quality standards, with certifications from renowned regulatory bodies like USFDA, DEA, WHO-GMP, and more. Recently, the USFDA issued three observations for the manufacturing facility of Havix Group Inc., a Material Subsidiary of Senores Pharmaceuticals, highlighting the company’s dedication to maintaining high-quality standards and regulatory compliance.
Read more from medicaldialogues.in